AOK: German Drug Costs to Rise Up to 2.8% in 2027 Despite Savings
Berlin – November 03, 2026 -- Net costs for outpatient drug care in Germany's statutory health insurance reached a record €62.6 billion, according to an analysis by the AOK's Scientific Institute (WIdO) on the 2027 pharmaceutical market. Dr. Carola Reimann, chair of the AOK Federal Association, warned that a planned location clause could erase the savings the current cost-containment package delivers.
WIdO projects 2027 drug cost growth of 2.2% to 2.8%
The institute attributes the moderate outlook to the higher manufacturer rebate for 2027. It expects drug costs to rise by 2.2% to a maximum of 2.8%. WIdO experts caution that the relief is short-lived and call for structural reform, above all of the AMNOG procedure, which governs the pricing of new drugs.